A minimally invasive procedure using electrical pulses in the small intestine shows promise in significantly improving type 2 diabetes, with benefits rivaling gastric bypass surgery.
April’s FDA approvals feature first-in-class therapies, targeted biologics, expanded indications, and innovative delivery systems across allergy, endocrinology, rheumatology, oncology, infectious diseases, and more.
A UK Biobank analysis identified 56 modifiable risk factors for sudden cardiac arrest; lifestyle improvements alone could prevent up to 18% of cases, with a total prevention potential of 63%.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.